Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations

Published:December 13, 2012DOI:https://doi.org/10.1016/j.ctrv.2012.11.004

      Abstract

      Malignant pleural mesothelioma (MPM) is a relevant public health issue. A large amount of data indicate a relationship between mesothelioma and asbestos exposure. MPM incidence has considerably and constantly increased over the past two decades in industrialized countries and is expected to peak in 2010–2020. In Italy, the standardized incidence rate in 2008 was 3.6 and 1.3 per 100,000 in men and women respectively, with wide differences from one region to another. The approach to this disease remains difficult and complex in terms of pathogenic mechanism, diagnosis, staging and treatment thus an optimal strategy has not yet been clearly defined. The Second Italian Multidisciplinary Consensus Conference on Malignant Pleural Mesothelioma was held in Turin (Italy) on November 24–25, 2011: recommendations on MPM management for public health institutions, clinicians and patients are presented in this report.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Cancer Treatment Reviews
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pinto C.
        • Ardizzoni A.
        • Betta P.G.
        • et al.
        Expert opinions of the first Italian consensus conference on the management of malignant pleural mesothelioma.
        Am J Clin Oncol. 2011; 34: 99-109
        • Schünemann H.J.
        • Oxman A.D.
        • Brozek
        • et al.
        GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies.
        Br Med J. 2008; 336: 1106-1110
      1. Marinaccio A. Quarto Rapporto Registro Nazionale Mesoteliomi ReNaM 2012, ongoing.

        • Montanaro F.
        • Rosato R.
        • Gangemi M.
        • et al.
        Survival of pleural malignant mesothelioma in Italy: a population-based study.
        Int J Cancer. 2009; 124: 201-207
      2. Howlader N, Noone A.M, Krapcho M, et al. SEER cancer statistics review, 1975–2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.

        • Gatta G.
        • Ciccolallo L.
        • Kunkler I.
        • et al.
        Survival from rare cancer in adults: a population-based study.
        Lancet Oncol. 2006; 7: 132-140
        • Montanaro F.
        • Bray F.
        • Gennaro V.
        • et al.
        Cancer Causes Control. 2003; 14: 791-803
        • Marinaccio A.
        • Montanaro F.
        • Mastrantonio M.
        • et al.
        Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models.
        Int J Cancer. 2005; 115: 142-147
        • Moolgavkar S.H.
        • Meza R.
        • Turim J.
        Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005.
        Cancer Causes Control. 2009; 20: 935-944
        • Park E.-K.
        • Takahashi K.
        • Hoshuyama T.
        • Cheng T.-J.
        • Delgermaa V.
        • Le G.V.
        • et al.
        Global magnitude of reported and unreported mesothelioma.
        Environ Health Perspect. 2011; 2011: 514-518
        • Pelucchi C.
        • Malvezzi M.
        • La Vecchia C.
        • et al.
        The Mesothelioma epidemic in Western Europe: an update.
        Br J Cancer. 2004; 90: 1022-1024
      3. NTP National Toxicology Program. Report on Carcinogens, U.S. Department of Health and Human Services, Public Health Service, Research Triangle Park; 2009.

      4. 2011 a review of human carcinogens: metals, arsenic, dusts, and fibres. 12th ed. IARC monographs on the evaluation of carcinogenic risks to humans. 100 C. WHO, IARC, Lyon2012
      5. Chrysotile Asbestos Expert Panel. Chrysotile Asbestos Consensus Statement and Summary, Montreal, Quebec, November 13–14, 2007.

        • Pan X.L.
        • Day H.W.
        • Wang W.
        • et al.
        Residential proximity to naturally occurring asbestos and mesothelioma risk in California.
        Am J Respir Crit Care Med. 2005; 172: 1019-1025
        • Ferrante D.
        • Bertolotti M.
        • Todesco A.
        • et al.
        Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy.
        Environ Health Perspect. 2007; 115: 1401-1405
        • Mirabelli D.
        • Cavone D.
        • Merler E.
        • et al.
        Non-occupational exposure to asbestos and malignant mesothelioma in the Italian national registry of mesotheliomas.
        Occup Environ Med. 2010; 67: 792-794
      6. Marinaccio A. Terzo Rapporto Registro Nazionale Mesoteliomi ReNaM. Istituto Superiore per la Prevenzione e la Sicurezza del Lavoro, Roma; 2010.

      7. IARC: monographs on the evaluation of the carcinogenic risk of chemicals to man. Preamble IARC. WHO, IARC, Lyon2006
      8. IARC: man-made mineral fibres. IARC monographs on the evaluation of carcinogenic risks to humans. 81. WHO, IARC, Lyon2002 (p. 1–381)
        • Utell M.J.
        • Maxim L.D.
        Refractory ceramic fiber (RCF) toxicity and epidemiology: a review.
        Inhal Toxicol. 2010; 22: 500-521
      9. NTP – National Toxicology Program. Report on carcinogens. background document for glass wool fibres. US Dept. Health, Research Triangle Park; 2009.

        • Lee K.P.
        • Barras C.E.
        • Griffith F.D.
        • et al.
        Comparative pulmonary responses to inhaled inorganic fibers with asbestos and fiberglass.
        Environ Res. 1981; 24: 167-191
        • Adachi S.
        • Kawamura K.
        • Takemoto K.
        A trial on the quantitative risk assessment of man-made mineral fibers by the rat intraperitoneal administration assay using the JFM standard fibrous samples.
        Ind Health. 2001; 39: 168-174
        • Johnson N.F.
        • Hahn F.F.
        Induction of mesothelioma after intrapleural inoculation of F344 rats with silicon carbide whiskers or continuous ceramic filaments.
        Occup Environ Med. 1996; 53: 813-816
        • Poland C.A.
        • Duffin R.
        • Kinloch I.
        • et al.
        Carbon nanotubes introduced into the abdominal cavity of mice show asbestos like pathogenicity in a pilot study.
        Nat Nanotechnol. 2008; 3: 423-428
        • Takagi A.
        • Hirose A.
        • Nishimura T.
        • et al.
        Induction of mesothelioma in p53 +/− mouse by intraperitoneal application of multi-wall carbon nanotube.
        J Toxicol Sci. 2008; 33: 105-116
        • Sakamoto Y.
        • Nakae D.
        • Fukumori N.
        • et al.
        Induction of mesotheliomaby a single intrascrotal administration of multi-wall carbon nanotube in intact male fischer 344 rats.
        J Toxicol Sci. 2009; 34: 65-76
        • Muller J.
        • Delos M.
        • Panin N.
        • et al.
        Absence of carcinogenic response to multiwall carbon nanotubes in a 2-years bioassay in the peritoneal cavity of the rat.
        Toxicol Sci. 2009; 110: 442-448
        • Goodman J.E.
        • Nascarella M.A.
        • Valberg P.A.
        Ionizing radiation: a risk factor for mesothelioma.
        Cancer Causes Control. 2009; 20: 1237-1254
        • Kjaerheim K.
        • Røe O.D.
        • Waterboer T.
        • et al.
        Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples.
        Int J Cancer. 2007; 120: 2459-2465
        • Gee G.V.
        • Stanifer M.L.
        • Christensen B.C.
        • et al.
        SV40 associated miRNAs are not detectable in mesotheliomas.
        Br J Cancer. 2010; 103: 885-888
        • Ugolini D.
        • Neri M.
        • Ceppi M.
        • et al.
        Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor.
        Mutat Res. 2008; 658: 162-171
        • Ascoli V.
        • Cavone D.
        • Merler E.
        • et al.
        Mesothelioma in blood related subjects: report of 11 clusters among 1954 italy cases and review of the literature.
        Am J Ind Med. 2007; 50: 357-369
        • Neri M.
        • Ugolini D.
        • Dianzani I.
        • et al.
        Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases.
        Mutat Res. 2008; 659: 126-136
        • Betti M.
        • Ferrante D.
        • Padoan M.
        • et al.
        XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
        Mutat Res. 2011; 708: 11-20
        • Testa J.R.
        • Cheung M.
        • Pei J.
        • Below J.E.
        • et al.
        Germline BAP1 mutations predispose to malignant mesothelioma.
        Nat Genet. 2011; 43: 1022-1025
        • Bott M.
        • Brevet M.
        • Taylor B.S.
        • et al.
        The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
        Nat Genet. 2011; 43: 668-672
        • Fubini B.
        • Fenoglio I.
        Toxic potential of mineral dusts.
        Elements. 2007; 3: 407-414
      10. NIOSH Current intelligence bulletin: asbestos fibers and other elongate mineral particles: state of the science and roadmap for research, version 4 – April 2011. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health.

        • Kane A.B.
        Kane A.B. Boffetta P. Saracci R. Wilbourn J.D. Mechanisms of mineral fibre carcinogenesis. IARC Scientific Publications. vol. 140. 1996
        • Huang S.X.L.
        • Jaurand M.C.
        • Kamp D.W.
        • et al.
        Role of mutagenicity in mineral fiber-induced carcinogenicity and other diseases.
        J Toxicol Environ Health B Crit Rev. 2011; 14: 179-245
        • Miserocchi G.
        • Sancini G.
        • Mantegazza F.
        • et al.
        Translocation pathways for inhaled asbestos fibers.
        Environ Health. 2008; 7: 4
        • Bianchi C.
        • Bianchi T.
        Susceptibility and resistance in the genesis of asbestos-related mesothelioma.
        Ind J Occup Environ Med. 2008; 12: 57-60
        • Carbone M.
        • Ly M.H.
        • Dodson R.F.
        • et al.
        Malignant mesothelioma: facts myths and hypotheses.
        J Cell Physiol. 2012; 227: 44-58
        • HEI health effects institute: asbestos research
        Asbestos in public and commercial buildings.
        Health Effects Institute – Asbestos Research, Cambridge (MA)1991
        • Hodgson J.T.
        • Darnton A.
        The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure.
        Ann Occup Hyg. 2000; 44: 565-601
        • Boffetta P.
        • Stayner L.T.
        Pleural and peritoneal neoplasms.
        in: Schottenfeld D. Fraumeni J.F. Cancer epidemiology and prevention. 3rd ed. Oxford University Press, 2006: 659-673
        • Berman D.W.
        • Crump K.S.
        A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type.
        Crit Rev Toxicol. 2008; 38: 49-73
        • Musk A.W.
        • De Klerk N.H.
        • Olsen N.J.
        • et al.
        Mortality in miners and millers of crocidolite in western australia: follow-up to 1999.
        Ann Occup Hyg. 2002; 46: 90-92
        • Peto J.
        • Seidman H.
        • Selikoff I.J.
        Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment.
        Br J Cancer. 1982; 45: 124-135
        • Berry G.
        • de Klerk N.H.
        • Reid A.
        • et al.
        Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom Western Australia.
        Occup Environ Med. 2004; 61: e14
        • Barone Adesi F.
        • Ferrante D.
        • Bertolotti M.
        • et al.
        Long-term mortality from pleural and peritoneal cancer after exposure to asbestos. Possible role of asbestos clearance.
        Int J Cancer. 2008; 123: 912-916
        • Moolgavkar S.H.
        • Meza R.
        • Turim J.
        Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005.
        Cancer Causes Control. 2009; 20: 935-944
      11. Tan E, Warren N. Mesothelioma mortality in Great Britain. The revised risk and two-stage clonal expansion models. Health and Safety Excutive (HSE); 2011. Research Report 876.

        • Harding A.H.
        • Darnton A.J.
        Asbestosis and mesothelioma among British asbestos workers (1971–2005).
        Am J Ind Med. 2010; 53: 1070-1080
        • Broaddus V.C.
        • Everitt J.I.
        • Black B.
        • et al.
        Non-neoplastic and neoplastic pleural endpoints following fiber exposure.
        J Toxicol Environ Hlt B. 2011; 14: 153-178
        • Russo A.
        • Bisanti L.
        Rapporto sui tumori a Milano. ASL della Città di Milano. XXXIII-IV. Zadig, Milano2007 (p. 9–74)
        • Watterson A.
        • Gorman T.
        • Malcolm C.
        • et al.
        The economic costs of health service treatments for asbestos-related mesothelioma deaths.
        Ann N Y Acad Sci. 2006; 1076: 871-881
        • Merler E.
        • Bressan V.
        • Bilato A.M.
        • et al.
        Gruppo regionale veneto sui mesoteliomi maligni. I fattori che influenzano in Italia la domanda e il riconoscimento dei mesoteliomi di origine professionale.
        Epidemiol Prev. 2011; 35: 331-338
        • Betta P.G.
        • Magnani C.
        • Bensi T.
        • et al.
        Immunohistochemistry and molecular diagnostic of pleural malignant mesothelioma.
        Arch Pathol Lab Med. 2012; 136: 253-261
      12. Butnor KJ, Beasley MB. Cagle PT, et al. Protocol for the examination of specimens from patients with malignant pleural mesothelioma. College of American Pathologists’ Recommendations; 2011: 1–12.

        • Ikeda K.
        • Tate G.
        • Suzuki T.
        • et al.
        Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
        Diagn Cytopathol. 2011; 39: 395-401
        • Creaney J.
        • Francis R.J.
        • Dick I.M.
        • et al.
        Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
        Clin Cancer Res. 2011; 17: 1181-1189
        • Hollevoet K.
        • Nackaerts K.
        • Gosselin R.
        • et al.
        Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
        J Thorac Oncol. 2011; 6: 1930-1937
        • Hollevoet K.
        • Nackaerts K.
        • Thimpont J.
        • et al.
        Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
        Am J Respir Crit Care Med. 2010; 181: 620-625
        • Luo L.
        • Shi H.Z.
        • Liang Q.L.
        • et al.
        Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
        Respir Med. 2010; 104: 149-156
        • Wheatley-Price P.
        • Yang B.
        • Patsios D.
        • et al.
        Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma.
        J Clin Oncol. 2010; 28: 3316-3322
        • Righi L.
        • Papotti M.G.
        • Ceppi P.
        • et al.
        Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
        J Clin Oncol. 2010; 28: 1534-1539
        • Bragdon B.
        • Moseychuk O.
        • Saldanha S.
        • et al.
        A bone morphogenetic proteins: a critical review.
        Cell Signal. 2011; 23: 609-620
        • Garland L.
        • Flores R.
        • Tsao A.
        Individualizing mesothelioma treatment: small steps into a brighter future.
        Clin Lung Cancer. 2010; 11: 371-373
        • Husain A.N.
        • Colby T.V.
        • Ordóñez N.G.
        • et al.
        Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the international mesothelioma interest group.
        Arch Pathol Lab Med. 2009; 133: 1317-1331
        • Zeng S.
        • Chen J.
        • Shen H.
        Controlling of bone morphogenetic protein signalling.
        Cellular Signal. 2010; 22: 888-893
      13. BTS statement on malignant mesothelioma in the UK.
        Thorax. 2007; 62: 1-19
        • Gill R.R.
        • Gerbaudo V.H.
        • Sugarbaker D.J.
        • et al.
        Current trends in radiologic management of malignant pleural mesothelioma.
        Semin Thorac Cardiovasc Surg. 2009; 21: 111-120
        • Raj V.
        • Kirke R.
        • Bankart M.J.
        • et al.
        Multidetector CT imaging of pleura: comparison of two contrast infusion protocols.
        Br J Radiol. 2011; 84: 796-799
        • Metintas M.
        • Ucgun I.
        • Elbek O.
        • et al.
        Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
        Eur J Radiol. 2002; 41: 1-9
        • Leung A.N.
        • Muller N.L.
        • Miller R.R.
        CT in differential diagnosis of diffuse pleural disease.
        Am J Rad. 1990; 154: 487-492
        • Knuuttila A.
        • Kivisaari L.
        • Kivisaari A.
        • et al.
        Evaluation of pleural disease using MR and CT with special reference to malignant pleural mesothelioma.
        Acta Radiol. 2001; 42: 502-507
        • Hierholzer J.
        • Luo L.
        • Bittner R.C.
        • et al.
        MRI and CT in the differential diagnosis of pleural disease.
        Chest. 2000; 118: 604-609
        • Heelan R.T.
        CT and MR imaging in the evaluation of pleural masses.
        Chest Surg Clin North Am. 1994; 3: 431-450
        • Duysinx B.
        • Nguyen D.
        • Louis R.
        • et al.
        Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
        Chest. 2004; 125: 489-493
        • Yildirim H.
        • Metintas M.
        • Entok E.
        • et al.
        Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
        J Thorac Oncol. 2009; 4: 1480-1484
        • Heelan R.T.
        • Rusch V.W.
        • et al.
        Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
        Am J Roentgenol. 1999; 172: 1039-1046
        • Plathow C.
        • Staab A.
        • Schmaeh A.
        • et al.
        Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma-initial results.
        Invest Radiol. 2008; 43: 737-744
        • Ambrosini V.
        • Rubello D.
        • Nanni C.
        • et al.
        Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
        Nucl Med Rev Cent East Eur. 2005; 8: 111-115
        • Plathow C.
        • Klopp M.
        • Thieke C.
        • et al.
        Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.
        Eur Radiol. 2008; 18: 1635-1643
        • Giesel F.L.
        • Bischoff H.
        • von Tengg-Kobligk H.
        • et al.
        Dynamic contrast enhanced MRI of malignant pleural mesothelioma––a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
        Chest. 2006; 129: 1570-1576
        • Oxnard G.R.
        Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
        Lung Cancer. 2006; 52: 41-48
        • Basu S.
        • Saboury B.
        • Torigian D.A.
        • et al.
        Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
        Mol Imaging Biol. 2011; 13: 801-811
        • Francis R.J.
        • Byrne M.J.
        • van der Schaaf A.A.
        • et al.
        Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
        J Nucl Med. 2007; 48: 1449-1458
        • Scherpereel A.
        • Astoul P.
        • Baas P.
        • Berghmans T.
        • et al.
        Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma.
        Eur Respir J. 2010; 35: 479-495
        • Stahel R.A.
        • Weder W.
        • Lievens Y.
        • et al.
        Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2010; 21: 126-128
        • Husain A.N.
        • Colby T.V.
        • Ordóñez N.G.
        • et al.
        Guidelines for pathologic diagnosis of malignant mesotelioma. A consensus statement from the international mesothelioma interest group.
        Arch Pathol Lab Med. 2009; 133: 1317-1331
        • Rahman N.M.
        • Gleeson F.V.
        Image-guided pleural biopsy.
        Curr Opin Pulm Med. 2008; 14: 331-336
        • Maskell N.A.
        • Gleeson F.V.
        • Davies R.J.
        Standard pleural biopsy versus CT guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.
        Lancet. 2003; 361: 1326-1330
        • Qureshi N.R.
        • Gleeson F.V.
        Imaging of pleural disease.
        Clin Chest Med. 2006; 27: 193-213
        • Adams R.F.
        • Gray W.
        • Davies R.J.
        • Gleeson F.V.
        Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.
        Chest. 2001; 120: 1798-1802
        • Metintas M.
        • Ak G.
        • Dundar E.
        • et al.
        Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
        Chest. 2010; 137: 1362-1368
        • Boutin C.
        • Rey F.
        Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis.
        Cancer. 1993; 72: 389-393
        • Hansen M.
        • Faurschou P.
        • Clementsen P.
        Medical thoracoscopy, results and complications in 146 patients: a retrospective study.
        Respir Med. 1998; 92: 228-232
        • Galbis J.M.
        • Mata M.
        • Guijarro R.
        • et al.
        Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century.
        Clin Transl Oncol. 2011; 13: 57-60
        • Brims F.J.H.
        • Arif M.
        • Chauhan A.J.
        • et al.
        Outcomes and complications following medical thoracoscopy.
        Clin Respir J. 2012; 6: 144-149
        • American joint committee on cancer: pleural mesothelioma
        7th ed. AJCC cancer staging manual. Springer, New York (NY)2010 (p. 271–4)
        • Kao S.C.
        • Yan T.D.
        • Lee K.
        • Burn J.
        • et al.
        Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.
        J Thorac Oncol. 2011; 6: 602-605
        • Rice D.C.
        • Steliga M.A.
        • Stewart J.
        • et al.
        Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
        Ann Thorac Surg. 2009; 88: 862-868
        • Tournoy K.G.
        • Burgers S.A.
        • Annema J.T.
        • et al.
        Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma.
        Clin Cancer Res. 2008; 14: 6259-6263
        • Zielinski M.
        • Hauer J.
        • Hauer L.
        • et al.
        Staging algorithm for diffuse malignant pleural mesotelioma.
        Interact CardioVasc Thorac Surg. 2010; 10: 185-189
        • Richards W.G.
        • Godleski J.J.
        • Yeap B.Y.
        • et al.
        Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases.
        Cancer. 2010; 116: 1510-1517
        • Muers M.F.
        • Stephens R.J.
        • Fisher P.
        • et al.
        Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
        Lancet. 2008 May; 17: 1685-1694
        • Van Meerbeeck J.P.
        • Gaafar R.
        • Manegold C.
        • et al.
        Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the national cancer institute of Canada.
        J Clin Oncol. 2005; 23: 6881-6889
        • Vogelzang N.J.
        • Rusthoven J.J.
        • Symanowski J.
        • et al.
        Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
        J Clin Oncol. 2003; 21: 2636-2644
        • Santoro A.
        • O’Brien M.E.
        • Stahel R.A.
        • et al.
        Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaıve patients with malignant pleural mesothelioma: results of the international expanded access program.
        J Thorac Oncol. 2008; 3: 756-763
        • Ceresoli G.L.
        • Castagneto B.
        • Zucali P.A.
        • et al.
        Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
        Br J Cancer. 2008; 99: 51-56
        • Kindler H.L.
        • Karrison T.
        • Gandara D.R.
        • et al.
        Multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
        J Clin Oncol. 2012; 30: 2509-2515
        • Zalcman G.
        • Margery J.
        • Scherpereel A.
        • et al.
        IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
        J Clin Oncol. 2010; 28 (Abstract 7020)
        • Jassem J.
        • Ramlau R.
        • Santoro A.
        • et al.
        Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
        J Clin Oncol. 2008; 26: 1698-1704
        • Razak A.R.
        • Chatten K.J.
        • Hughes A.N.
        Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
        Lung Cancer. 2008; 60: 294-297
        • Serke M.
        • Bauer T.
        Pemetrexed in second-line therapy in patients with malignant pleural mesotelioma.
        J Clin Oncol. 2007; 25 (Abstract 18198)
      14. De Vincenzo F, Zucali PA, Ceresoli GL, et al. Re-treatment with pemetrexed based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. In: Proceedings of the IX International Conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands); 2008. Abstract 163.

        • Kolschmann S.
        • Ballin A.
        • Gillissen A.
        Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
        Chest. 2005; 128: 1431-1435
        • Rusch V.W.
        • Venkatraman E.
        The importance of surgical staging in the treatment of malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 1996; 111: 815-825
        • Rusch V.W.
        Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
        Sem Thorac Cardiovasc Surg. 1997; 9: 367-372
        • Rusch V.W.
        • Piantadosi S.
        • Holmes E.C.
        The role of extrapleural pneumonectomy in malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 1991; 102: 1-9
        • Sugarbaker D.J.
        • Strauss G.M.
        • Lynch T.J.
        • et al.
        Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
        J Clin Oncol. 1993; 11: 1172-1178
        • Sugarbaker D.J.
        Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
        J Thorac Oncol. 2006; 1: 175-176
        • Aziz T.
        • Jilaihawi A.
        • Prakash D.
        The management of malignant pleural mesothelioma; single centre experience in 10 years.
        Eur J Cardiothorac Surg. 2002; 22: 298-305
        • Pilling J.E.
        • Stewart D.J.
        • Martin-Ucar A.E.
        • et al.
        The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
        Eur J Cardiothorac Surg. 2004; 25: 497-501
        • Rice D.C.
        • Erasmus J.J.
        • Stevens C.W.
        • et al.
        Extended surgical staging for potentially resectable malignant pleural mesothelioma.
        Ann Thorac Surg. 2005; 80: 1988-1992
        • Stewart D.J.
        • Martin-Ucar A.
        • Pilling J.E.
        • et al.
        The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
        Ann Thorac Surg. 2004; 78: 245-252
        • Edwards J.G.
        • Stewart D.J.
        • Martin-Ucar A.E.
        • et al.
        The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
        J Thorac Cardiovasc Surg. 2006; 131: 981-987
        • Janne P.A.
        • Baldini E.H.
        Patterns of failure following surgical resection for malignant pleural mesothelioma.
        Thorac Surg Clin. 2004; 14: 567-573
        • Mahe M.A.
        • Cellerin L.
        • Michaud J.L.
        • et al.
        Recent progress in treatment of malignant pleural mesothelioma.
        Cancer Radiother. 2005; 9: 362-365
        • Martin-Ucar A.E.
        • Nakas A.
        • Edwards J.G.
        • et al.
        Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
        Eur J Cardiothorac Surg. 2007; 31: 765-771
        • Neragi-Miandoab S.
        Multimodality approach in management of malignant pleural mesothelioma.
        Eur J Cardiothorac Surg. 2006; 29: 14-19
        • Grunenwald D.
        Malignant pleural mesothelioma. Role of surgery.
        Rev Pneumol Clin. 2005; 61: 8-9
        • Gupta V.
        • Mychalczak B.
        • Krug L.
        • et al.
        Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1045-1052
        • Flores R.M.
        • Akhurst T.
        • Gonen M.
        • et al.
        Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 2003; 126: 11-16
        • Flores R.M.
        • Krug L.M.
        • Rosenzweig K.E.
        • et al.
        Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
        J Thorac Oncol. 2006; 1: 289-295
        • Flores R.M.
        • Zakowsky M.
        • Venkatraman E.
        • et al.
        Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.
        J Thorac Oncol. 2007; 2: 957-965
        • Flores R.M.
        • Pass H.I.
        • Seshan V.E.
        • et al.
        Extrapleural pneumonectomy cersus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
        J Thorac Cardiovasc Surg. 2008; 135: 620-626
        • Rice D.
        Surgery for malignant pleural mesothelioma.
        Ann Diagn Pathol. 2009; 13: 65-72
        • Weder W.
        • Kestenholtz P.
        • Taverna C.
        • et al.
        Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
        J Clin Oncol. 2004; 22: 3451-3457
        • Weder W.
        • Stahel R.A.
        • Bernhard J.
        • et al.
        Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
        Ann Oncol. 2007; 18: 1196-1202
        • de Perrot M.
        • Feld R.
        • Cho B.C.
        • et al.
        Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
        J Clin Oncol. 2009; 27: 1413-1418
        • Kaufman A.J.
        • Flores R.M.
        Surgical treatment of malignant pleural mesothelioma.
        Curr Treat Options Oncol. 2011; 12: 201-216
        • Rice D.
        • Rusch V.
        • Pass H.
        • et al.
        Recommendations for uniform definitions of surgical techniques for malignant pleuralmesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.
        J Thorac Oncol. 2011; 6: 1304-1312
        • Rice D.
        Surgical therapy of mesothelioma.
        Recent Results Cancer Res. 2011; 189: 97-125
        • Treasure T.
        • Lang-Lazdunski L.
        • Waller D.
        • et al.
        Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study.
        Lancet Oncol. 2011; 12: 763-772
        • Price A.
        What is the role of radiotherapy in malignant pleural mesothelioma?.
        Oncologist. 2011; 16: 359-365
        • Ung Y.C.
        • Yu E.
        • Falkson C.
        • et al.
        The role of radiation therapy in malignant pleural mesothelioma: a systematic review.
        Radiother Oncol. 2006; 80: 13-18
        • Boutin C.
        • Rey F.
        • Viallat J.R.
        Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
        Chest. 1995; 108: 754-758
        • Bydder S.
        • Philips M.
        • Joseph D.J.
        • et al.
        A randomised trial of single dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma.
        Br J Cancer. 2004; 91: 9-10
        • O’Rourke N.
        • Garcia G.C.
        • Paul J.
        • et al.
        A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
        Radiother Oncol. 2007; 84: 18-22
        • De Graaf-Strukowska L.
        • Van der Zee J.
        • Van Putten W.
        • et al.
        Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single institution experience with 189 patients.
        Int J Radiat Oncol Biol Phys. 1999; 43: 511-516
        • De Ruysscher D.
        • Slotman B.
        Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch–Belgian survey.
        Radiother Oncol. 2003; 68: 299-302
        • Davis S.R.
        • Tan L.
        • Ball D.L.
        Radiotherapy in the treatment of malignant mesothelioma with special reference to its use in palliation.
        Aust Radiol. 1994; 38: 212-214
        • Bissett D.
        • Macbeth F.R.
        • Cram I.
        • et al.
        The role of palliative radiotherapy in malignant mesothelioma.
        Clin Oncol. 1991; 3: 315-317
        • Linden C.J.
        • Mercke C.
        • Albrechtsson U.
        • et al.
        Effect of hemithorax irradiation alone or combined with doxorubicin and cyclofosfamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
        Eur Respir J. 1996; 9: 2565-2572
        • Baldini E.H.
        • Rech A.
        • Strass G.M.
        • et al.
        Patterns of failure after trimodality therapy for malignant mesothelioma.
        Ann Thorac Surg. 1997; 63: 334-338
        • Jaklitsch M.T.
        • Grondi S.C.
        • Sugarbaker D.J.
        Treatment of malignant mesothelioma.
        World J Surg. 2001; 25: 210-217
        • Rusch V.W.
        • Rosenzweig K.
        • Venkatraman E.
        • et al.
        A phase II trial of surgical resection and adjuvant high-dose hemothoracic radiation for malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 2001; 122: 788-795
        • Sugarbaker D.J.
        • Flores R.M.
        • Jaklitsch M.T.
        • et al.
        Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy for malignant pleural mesothelioma: results in 183 patients.
        J Thorac Cardiovasc Surg. 1999; 117: 54-63
        • Van Meerbeeck J.P.
        • Scherpereel A.
        • Surmont V.F.
        • et al.
        Malignant pleural mesothelioma: the standard of care and challenges for future management.
        Crit Rev Oncol Hematol. 2011; 78: 92-111
        • Ahamed A.
        • Stevens C.W.
        • Smythe W.R.
        • et al.
        Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
        Int J Radiat Oncol Biol Phys. 2003; 55: 768-775
        • Ahamed A.
        • Stevens C.W.
        • Smythe W.R.
        • et al.
        Promising early local control of malignant pleural mesothelioma following postoperative Intensity Modulated Radiotherapy (IMRT) to the chest.
        Cancer J. 2003; 9: 476-484
        • Allen A.M.
        • Den R.
        • Wong J.S.
        • et al.
        Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1366-1374
        • Yan T.D.
        • Boyer M.
        • Tin M.M.
        • et al.
        Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
        J Thorac Cardiovasc Surg. 2009; 138: 619-624
        • Allen A.M.
        • Czerminska M.
        • Janne P.A.
        • et al.
        Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
        Int J Radiat Oncol Biol Phys. 2006; 65: 640-645
        • Rice D.C.
        • Smythe W.R.
        • Liao Z.
        • et al.
        Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
        Int J Radiat Oncol Biol Phys. 2007; 69: 350-357
        • Hill-Kayser C.E.
        • Avery S.
        • Mesina C.F.
        • et al.
        Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.
        J Thorac Oncol. 2009; 4: 1431-1437
        • Tonoli S.
        • Vitali P.
        • Scotti V.
        • et al.
        Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.
        Radiother Oncol. 2011; 101: 311-315
        • Rusch V.W.
        Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
        Chest. 1993; 103: 382-384